Early detection of cardiomyopathy in patients receiving Anthracycline chemotherapy and determine if speckle tracking echo and Troponin gene will add benefit for early detection of cardiomyopathy. Improve economic impact of oncologic patients from whom high sensitive troponin negative and normal speckle tracking patients can be safely excluded from long-term cardiac monitoring programs. To correlate between the molecular gene expression of troponin genes and ryanodine receptor in cardiomyopathy
Full Title of Study: “Added Benefit of Speckle Tracking Echo to Molecular Expression of High Sensitive Troponin I and Cardiac Ryanodine Receptor in Early Detection of Cardiomyopathy in Patients Receiving Anthracycline Chemotherapy”
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: January 1, 2019
Anthracycline chemotherapy has saved the lives of many cancer victims during the 50 years after their discovery.These patients are prone to higher risk of cardiovascular death than the risk of tumor recurrence, particularly in childhood cancer survivors in whom the cardiac mortality rate is seven fold higher. Cardiac toxicity remains an important side effect of anticancer therapies, leading to increased mortality due to mainly heart failure, but also arrhythmias, hypertension, thromboembolism. The time from early development of cardiac dysfunction to the modification or end of chemotherapy and beginning of heart failure therapy, is an important determinant of the extent of recovery. The Cardiotoxicity of anthracyclines may be acute, early or late. A recent study involving 2625 patients (mean follow-up 5 years); showed a 9% overall incidence of Cardiotoxicity after anthracycline treatment, 98% of cases occurred within the first year and were asymptomatic. Cardiotoxicity has been defined using various classifications. Recent guidelines suggest that Cancer therapeutics-related cardiac dysfunction (CTRCD) is defined as a decrease in the LVEF (by echocardiography) of >10 percentage points to a value below the lower limit of normal. Echocardiography should be repeated before every next administration of anthracycline, after 3, 6, and 12 months from the end of therapy with anthracycline but…Not all patients treated with chemotherapy require such frequently repeated LVEF monitoring as suggested by the guidelines because of the negative impact on patient management and cost-effectiveness ratio for the national health system. Speckle-tracking echocardiography is a noninvasive ultrasound imaging technique that allows for early an objective and quantitative evaluation of global and regional myocardial function. New elevation of serum troponin detected with high sensitivity Troponin assays in patients receiving anthracyclines also predicts subsequent LV dysfunction. Ryanodine receptors (RyRs) are a class of intracellular calcium channels in various forms of excitable tissues like muscles and neurons. In heart failure the RyR2 channels become abnormally active or "leaky" and are unable to remain closed during diastole. This leads to an increase in spontaneous Ca+2 spark frequency and dysregulated Ca+2 handling within the cardiomyocyte, resulting in decreased systolic contraction and irregular contractile activity.
- Drug: Chemotherapy, Cancer, Anthracyclines
- follow up cardio-toxicity …. by speckle tracking echo and cardiac troponin
Clinical Trial Outcome Measures
- early detection of cardiomyopathy
- Time Frame: about one year
- using speckle tracking echo to early diagnosis of cardiomyopathy
- identify patients whose at risk to develop cardiomyopathy
- Time Frame: about one year
- Using the high sensitive troponin with quantitative measurements as biomarker.
- molecular gene expression of troponin genes and ryanodine receptor in cardiomyopathy
- Time Frame: same time frame … about one year
- quantitative correlation between the troponin genes and ryanodine receptor in early cardiomyopathy
Participating in This Clinical Trial
- all Newly diagnosed cancer patients with who will receive Anthracycline based regimen chemotherapy Exclusion Criteria:
- Insufficient ultrasound image quality, defined as more than three LV segments being suboptimally visualized by conventional echocardiography. – Valvular heart disease – Hypertensive heart disease – Cardiomyopathy – Chronic renal failure – Chronic obstructive air way disease (COPD)
Gender Eligibility: All
Minimum Age: 30 Years
Maximum Age: 50 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Assiut University
- Provider of Information About this Clinical Study
- Principal Investigator: Mostafa Mahmoud Morsy, doctor – Assiut University
- Overall Official(s)
- yehia T kishk, MD, Study Chair, cardiology department
- Mohamed K Koriem, MD, Principal Investigator, cardiology department
- Naglaa K Idriss, MD, Principal Investigator, biochemistry department
- Overall Contact(s)
- Mostafa M Morsy, MD, +201096955959, Mostafa_corono@yahoo.com
Citations Reporting on Results
Henning RJ, Harbison RD. Cardio-oncology: cardiovascular complications of cancer therapy. Future Cardiol. 2017 Jul;13(4):379-396. doi: 10.2217/fca-2016-0081. Epub 2017 Jun 29. Review.
Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016 Jul;66(4):309-25. doi: 10.3322/caac.21341. Epub 2016 Feb 26. Review.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.